Brief: FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection For Maintenance Dosing For The Treatment Of Early Alzheimer's Disease
29/08/2025 22:14
Aug 29 (Reuters) - Eisai Co Ltd 4523.T: FDA APPROVES LEQEMBI® IQLIK™ (LECANEMAB-IRMB) SUBCUTANEOUS INJECTION FOR MAINTENANCE DOSING FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE Source text: ID:nPnbj4qBca Further company coverage: 4523.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China